

Fig. 1

Fig. 1A




Fig. 1B




Fig. 2A





Fig. 2B






Fig. 3B




Fig. 3C




Fig. 4A




Fig. 4B




Fig. 4C



Fig. 4D




Fig. 5A





Fig. 5B






Fig. 7A




Fig. 7B




Fig. 7C




Fig. 7D




Fig. 7E





Fig. 7F



Her2 (PER)-4-1BBL
Her2 (aff-PER)-4-1BBL
DP47-4-BBL
Her2 (TRAS)-anticalin-4-1BB hulG4
(fusion polypeptide of SEQ ID NOs 9 and 10 described in patent WO2016177802)
DP47-anticalin 4-1BB hulG4

anti-human 4-1BB clone 20H4.9 hulG4 (described in patents EP1670828B1 and US7659384(B2))
anti-human 4-1BB clone MOR-7480 hulG2 (described in patent WO2012032433)
Her2 (PER) hulG1 PGLALA
DP47 hulG1 PG LALA

Fig. 8A





Fig. 8B



● Her2 (PER)-4-1BBL
■ Her2 (TRAS)-4-1BBL
□ DP47-4-BBL

● Her2 (TRAS)-anticalin 4-1BB hulG4
(fusion polypeptide of SEQ ID NOs 9 and 10 described in patent WO2016177802)
□ DP47-anticalin 4-1BB hulG4

Fig. 8C





Fig. 8D







Fig. 9




Fig. 10A




Fig. 10B




Fig. 10C




Fig. 10D




Fig. 10E





Fig. 10F



● Her2 (PER) 4-1BBL
■ Her-2 (TRAS) 4-1BBL
◆ DP47 4-BBL

● Her2 (TRAS)-anticalin-4-1BB hulG4
(fusion polypeptide of SEQ ID NOs 9 and 10 described in patent WO2016177802)

◆ DP47-anticalin-4-1BB hulG4

■ anti-human 4-1BB clone 20H4.9 hulG4 (described in patents EP1670828B1 and US7659384(B2))
◆ anti-human 4-1BB clone MOR-7480 hulG2 (described in patent WO2012032433)

● Her2 (PER) hulG1 PG LALA
◆ DP47 hulG1 PG LALA

Fig. 11A




Fig. 11B





Fig. 11C



Her2 (PER)-4-1BBL
Her-2 (TRAS)-4-1BBL
DP47-4-BBL
Her2 (TRAS)-anticalin-4-1BB hulG4
(fusion polypeptide of SEQ ID NOS 9 and 10 described in patent WO2016177802)
DP47-anticalin-4-1BB hulG4

Fig. 11D




Fig. 11E





Fig. 11F



anti-human 4-1BB clone 20H4.9 hulG4 (described in patents EP1670828B1 and US7659384(B2))
anti-human 4-1BB clone MOR-7480 hulG2 (described in patent WO2012032433)
Her2 (PER) hulG1 PG LALA
DP47 hulG1 PG LALA

Fig. 12




Fig. 13A




Fig. 13B




Fig. 13C





Fig. 13D



mu4-1BB mAb DAPG

mu4-1BB-Her2

Fig. 14B

Cell killing




Fig. 14A

T cell activation




Fig. 15A

Fig. 15B

Her2(PER)-4-1BBL promotes CD8+ T cell proliferation Her2(PER)-4-1BBL supports greater CD8+ T cell numbers




Fig. 16A




Fig. 16B




Fig. 16C




Fig. 16D

